Myricx Bio

Biotechnology company developing next-generation antibody-drug conjugates (ADCs) for cancer therapy, using innovative linker-payload technologies to improve efficacy and safety.

Location
London, United Kingdom
Founded
2019
Investors
2
Categories
therapeutics, biotech, oncology, adc, antibody-drug-conjugates

Investors

NameLocationTypeStagesPortfolio
Novo HoldingsHellerup, Denmarkbiotech-focused
seedseries-a+3
13
AbingworthLondon, UK / Boston, USAbiotech-focused
seedseries-a+3
34